New directions in non-small cell lung cancer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalSeminars in Oncology
Volume17
Issue number4 SUPPL. 7
StatePublished - 1990
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Folic Acid Antagonists
Anthracyclines
Cisplatin
Monoclonal Antibodies
Drug Therapy
Survival
Therapeutics
Neoplasms
Direction compound
Clinical Studies
10-deazaaminopterin

ASJC Scopus subject areas

  • Oncology

Cite this

New directions in non-small cell lung cancer. / Gralla, Richard J.

In: Seminars in Oncology, Vol. 17, No. 4 SUPPL. 7, 1990, p. 14-19.

Research output: Contribution to journalArticle

@article{d8d6a893c4ab4851abe0191c273d68cb,
title = "New directions in non-small cell lung cancer",
abstract = "A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.",
author = "Gralla, {Richard J.}",
year = "1990",
language = "English (US)",
volume = "17",
pages = "14--19",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 7",

}

TY - JOUR

T1 - New directions in non-small cell lung cancer

AU - Gralla, Richard J.

PY - 1990

Y1 - 1990

N2 - A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.

AB - A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.

UR - http://www.scopus.com/inward/record.url?scp=0025088689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025088689&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 14

EP - 19

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 7

ER -